Ofatumumab: A novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia;Ofatumumab: Un novedoso anticuerpo monoclonal anti-cd20 para el tratamiento de la leucemia linfocítica crónica (LLC) refractaria

Annals of Pharmacotherapy

Volumn 45, Issue 10, 2011, Pages 1248-1255

  Nightingale, Ginah ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CD 20 monoclonal antibody; Chronic lymphocytic leukemia; HuMax Cd20; Ofatumumab

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; CETIRIZINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MONOCLONAL ANTIBODY; OFATUMUMAB; PREDNISONE; RITUXIMAB;

ADULT; ANEMIA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DATA EXTRACTION; DIARRHEA; DRUG BINDING; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDLINE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; DRUG MONITORING; DRUG RESISTANCE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 80053940562     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P780     Document Type: Review

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010;60:277-300.
2. Shanafelt TD, Call TG. Current approach to diagnosis and management of chronic lymphocytic leukemia. Mayo Clin Proc 2004;79:388-98.
3. Dighiero G, Hamblin TJ. Chronic lymphocytic leukemia. Lancet 2008; 371:1017-29.
4. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
5. Hallek M, Fingerle-Rowson G, Fink AM, et al. First-line treatment with fludarabine, cyclophosphamide, and rituximab improves overall survival in previously untreated patients with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group (abstract 535). Blood 2009;114:223-4.
6. The NCCN clinical practice guidelines in oncology non-Hodgkin's lymphomas (version 1.2011). 2010 National Comprehensive Cancer Network, Inc. www.NCCN.org (accessed 2011 May 20).
7. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376: 1164-74.
8. Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48:1931-9.
9. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71.
10. Li B, Zhao L, Guo H, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009;114:5007-15.
11. Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008;140:303-12.
12. Package insert. Arzerra (ofatumumab). Research Triangle Park, NC: GlaxoSmithKline, September 2010.
13. Cancer therapy evaluation program, common terminology criteria for adverse events, version 4.0, DCTD, NCI, NIH, DHHS. Published August 9, 2006. http://ctep.cancer.gov (accessed 2011 Jun 1).
14. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1-2 study. Blood 2008;111:1094-100.
15. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55.
16. Wierda WG, Kipps TJ, Mayer J, et al. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia (abstract 921). American Society of Hematology Annual Meeting Proceedings Part 2. 2010.
17. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7.
18. Hillmen P. Advancing therapy for chronic lymphocytic leukemia-the role of rituximab. Semin Oncol 2002;29(suppl 2):22-6.
19. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;35:5616-23.
20. Badoux X, O'Brien S, Wierda WG, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: results of a Phase II trial (abstract 2464). ASH Annual Meeting Proceedings Part 2. 2010.
21. Wierda WG, Kipps TJ, Durig J, et al. Ofatumumab combined with fludarabine and cyclophosphamide (O -FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multi-center, international, two-dose, parallel group, phase II trial (abstract 207). Blood 2009;114:90.
22. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111:5486-95.
23. Coiffier B, Bosly A, Wu KL, et al. Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multi-center Phase II study (abstract 3955). ASH Annual Meeting Proceedings Part 2. 2010.
24. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab (HuMax-CD20), a fully human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis. Early results from an ongoing, double-blind, randomized, placebo controlled clinical trial. Ann Rheum Dis 2007;66(suppl 2):124.
25. GlaxoSmithKline. NCT00603525: Investigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to TNF-F020;antagonist. www.clinicaltrials.gov (accessed 2011 Jun 1).
26. GlaxoSmithKline. NCT00611455: Investigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to methotrexate therapy. www.clinicaltrials.gov (accessed 2011 Jun 1).
27. Genmab. NCT00640328: Ofatumumab dose-finding in relapsing remitting multiple sclerosis patients. www.clinicaltrials.gov (accessed 2011 Jun 1).
28. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170-80.
29. Red book. 2010 ed. Montvale, NJ: Thomson Healthcare Inc., 2010.